JAM-A promotes wound healing by enhancing both homing and secretion activities of mesenchymal stem cells

The homing ability and secretory function of mesenchymal stem cells (MSCs) are key factors that influence the cells’ involvement in wound repair. These factors are controlled by a multilayer regulatory circuitry, including adhesion molecules, core transcription factors (TFs), and certain other regulators. However, the role of adhesion molecules in this regulatory circuitry and their underlying mechanism remain undefined. Here, we demonstrate that an adhesion molecule, junction adhesion molecule A (JAM-A), may function as a key promoter molecule that regulates skin wound healing by MSCs. In in vivo experiments, we show that JAM-A up-regulation promoted both MSC homing to full-thickness skin wounds and wound healing-related cytokine secretion by MSCs. In vitro experiments also showed that JAM-A promoted MSC proliferation and migration by activating T-cell lymphoma invasion and metastasis 1(Tiam1). We suggest that JAM-A up-regulation can increase the proliferation, cytokine secretion and wound-homing ability of MSCs, thus accelerating the rate of repair of full-thickness skin defects. These results may provide insights into a novel and potentially effective approach to improve the efficacy of MSC treatment.
Source: Clinical Science - Category: Biomedical Science Authors: Source Type: research

Related Links:

Condition:   NK/T Cell Lymphoma Nos Intervention:   Drug: sintilimab,pegaspargase,gemcitabine,oxaliplatin Sponsor:   Sun Yat-sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this study, we investigated the expression and function of YKL-40 in cutaneous T-cell lymphoma (CTCL).
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Original Article Source Type: research
Non-Hodgkin lymphoma (NHL) is typically sensitive to conventional doses of chemotherapy but many patients do not respond to front-line treatment or subsequently relapse after achieving remission. For medically-fit patients with relapsed/refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), subsequent treatment with high dose chemotherapy and autologous hematopoietic stem cell transplantation (ASCT) is often indicated [1 –4]. ASCT is also performed as consolidation treatment for patients with mantle cell lymphoma (MCL) and peripheral T-cell lymphoma (PTCL) and is associated with favorable progr...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Breast implant –associated anaplastic large cell lymphoma (BIA-ALCL) is a CD30-positive, anaplastic lymphoma kinase–negative T-cell lymphoma. Nearly all cases have been associated with textured implants. Most cases are of effusion-limited, indolent disease, with an excellent prognosis following implant and cap sule removal. However, capsular invasion and tumor mass has a more aggressive course, and a fatal outcome risk. This review summarizes the current knowledge on BIA-ALCL cell of origin and immunological factors underlying its pathogenesis.
Source: American Journal of Pathology - Category: Pathology Authors: Tags: Review Source Type: research
Raquel Aragón-Miguel, Alba Calleja-Algarra, Virginia Velasco-Tamariz, María Garrido, Pablo Ortiz-Romero, Lidia Maroñas-JiménezIndian Journal of Dermatology, Venereology, and Leprology 2019 85(6):656-659
Source: Indian Journal of Dermatology, Venereology and Leprology - Category: Dermatology Authors: Source Type: research
This article is protected by copyright. All rights reserved
Source: Biotechnology and Applied Biochemistry - Category: Biochemistry Authors: Tags: Original Article Source Type: research
Primary mediastinal non-Hodgkin lymphomas (PM-NHLs) represent ~5% of all NHLs and comprise lymphomas of B-cell and T-cell origin. PM-NHLs are defined as involvement of mediastinal lymph nodes, thymus, and/or mediastinal organs (heart, lung, pleura, pericardium) by NHL without evidence of systemic disease at presentation. The clinical scenario is variable and depends on the lymphoma subtype. The radiologic presentation is also variable ranging from a mediastinal mass with or without superior vena cava syndrome, a pleural or a cardiac mass associated with an effusion, or as an effusion only. The diagnosis of PM-NHLs can only...
Source: Advances in Anatomic Pathology - Category: Pathology Tags: Review Articles Source Type: research
Primary mediastinal non-Hodgkin lymphomas (PM-NHLs) represent ∼5% of all non-Hodgkin lymphomas (NHLs) and comprise lymphomas of B-cell and T-cell origin. PM-NHLs are defined as involvement of mediastinal lymph nodes, thymus, and/or mediastinal organs (heart, lung, pleura, pericardium) by NHL without evidence of systemic disease at presentation. The clinical scenario is variable and depends on the lymphoma subtype. The radiologic presentation is also variable ranging from a mediastinal mass with or without superior vena cava syndrome, a pleural or a cardiac mass associated with effusion, or as an effusion only. The diag...
Source: Advances in Anatomic Pathology - Category: Pathology Tags: Review Articles Source Type: research
Authors: Nakamura T, Takai Y, Kaneko K, Kuroda H, Misu T, Asanuma K, Saito R, Aoki M Abstract A 66-year-old woman presented with upper abdominal pain and weakness in the limbs. She had bilateral uveitis and gastric ulcers. A neurological examination revealed tetraparesis and sensory disturbance in the right arm. A cerebrospinal fluid (CSF) examination showed polymorphonuclear pleocytosis with elevated pro-inflammatory cytokine levels. Magnetic resonance imaging showed brain lesions and a long spinal cord lesion. She was initially diagnosed with neuro-Behçet's disease and was treated with corticosteroids, res...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Biomedical Science | Gastroschisis Repair | Lymphoma | Science | Skin | Stem Cell Therapy | Stem Cells | T-cell Lymphoma